New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
08:34 EDTIMMUImmunomedics announces U.S. patent for IMMU-144
Immunomedics announced the issuance of U.S. patent no. 8,722,047 for the company's patent application "Humanized anti-HLA-DR antibodies," with an expiration date of May 26, 2026. The new patent concerns compositions of humanized anti-HLA-DR antibodies of use for disease therapy. The allowed claims protect IMMU-114, which is being investigated as a monotherapy in a newly-opened Phase I dose-escalation trial in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
12:33 EDTIMMUImmunomedics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
09:32 EDTIMMUImmunomedics granted breakthrough therapy designation for sacituzumab govitecan
Immunomedics announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease.
09:29 EDTIMMUImmunomedics granted Breakthrough Therapy Designation from FDA for IMMU-132
Subscribe for More Information
February 3, 2016
16:05 EDTIMMUImmunomedics sees Phase 3 PANCRIT-1 trial completing enrollment in 2016
Subscribe for More Information
16:03 EDTIMMUImmunomedics reports Q2 EPS (15c), two estimates (14c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use